Select year

2026 2025 2024 2023 2022 Earlier

shown/page

20

2024.11.18

Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

2024.10.17

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

2024.10.15

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

2024.07.23

NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment
NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment

2024.07.19

Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes
Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes

2024.06.08

Chipscreen Biosciences' Chidamide tablets designated as a breakthrough therapy for advanced colorectal cancer
Chipscreen Biosciences' Chidamide tablets designated as a breakthrough therapy for advanced colorectal cancer

2024.04.30

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

2024.04.25

“Chinese Researchers + Innovative Drugs” Shine on the Global Stage | Chidamide Clinical Studies Selected for 2024 ASCO LBA and Multiple Presentations
“Chinese Researchers + Innovative Drugs” Shine on the Global Stage | Chidamide Clinical Studies Selected for 2024 ASCO LBA and Multiple Presentations

2024.03.18

Wang Cheng, Secretary of the Party Committee and Chairman of Sichuan Energy Investment, and his team visited Chipscreen Biosciences for inspection and survey
Wang Cheng, Secretary of the Party Committee and Chairman of Sichuan Energy Investment, and his team visited Chipscreen Biosciences for inspection and survey

2024.03.18

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

2024.03.04

CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer
CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer

Media contact

Media contact

（+86）0755-36993500
pr@juliucq.com